MYOV News and Press, Myovant Sciences Ltd. From 01/26/21

Myovant Sciences (MYOV) and Pfizer (PFE) have announced data from Phase 3 SPIRIT long-term extension study evaluating relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg in women with endometriosis.84.8% and 73.3% of women reported clinically meaningful reductions in d...

84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year 82.8% average reduction from baseline on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain) ov...

The following slide deck was published by Myovant Sciences Ltd. in conjunction with this event. For further details see: Myovant Sciences (MYOV) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

After recording back-to-back losses, Myovant Sciences (MYOV) ended flat today after Goldman Sachs downgraded the stock to Neutral from Buy with the 12-month price target maintained at $30, 23.9% of upside to today’s close.In December, the FDA granted approval for Orgovyx, the...

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the release, the presentation time should be 2:50 p.m. Eastern Time, not 2:50 p.m. Pacific Time as pre...

Myovant Sciences ([[MYOV]] +0.9%) announced that ORGOVYX™ is approved by the U.S. FDA for the treatment of adult patients with advanced prostate cancer. “Myovant has been focused on ensuring access to ORGOVYX for men with advanced prostate cancer as quickly as possible foll...

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual ...

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix), the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonis...

Myovant Sciences (MYOV) appointed David Marek as chief executive officer to succeed Lynn Seely, M.D.Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board. Marek is a veteran biopharmaceutical executive with...

BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also ...